Clinical and histopathologic evaluation of the effect of 17-alpha-hydroxyprogesterone-17-n-caproate on endometral carcinoma.
D000077713:17 alpha-Hydroxyprogesterone Caproate; D019326:17-alpha-Hydroxyprogesterone; D000230:Adenocarcinoma / Q000628:therapy*; D000231:Adenocarcinoma, Papillary / Q000628:therapy*; D002208:Caproates; D005260:Female; D006801:Humans; D006908:Hydroxyprogesterones; D011374:Progesterone / Q000031:analogs & derivatives; D014594:Uterine Neoplasms / Q000628:therapy*
D002208:Caproates; D006908:Hydroxyprogesterones; D000077713:17 alpha-Hydroxyprogesterone Caproate; D011374:Progesterone; D019326:17-alpha-Hydroxyprogesterone
ADENOCARCINOMA, PAPILLARY/therapy; ADENOCARCINOMA/therapy; PROGESTERONE/related compounds; UTERUS NEOPLASMS/therapy